Pharmacokinetic and Pharmacodynamic Interactions between Glimepiride-Metformin Combination and Angiotensin Receptor Blockers: Necessity, Current Evidence and Future Research Directions

Type 2 diabetes mellitus (T2DM) frequently coexists with hypertension, substantially increasing the risk of cardiovascular morbidity, mortality, and progressive renal disease. Contemporary management of these comorbid conditions relies heavily on polypharmacy, with oral antidiabetic drugs and antihypertensive agents prescribed concomitantly for prolonged durations. Among antidiabetic therapies, the fixed-dose combination of glimepiride and metformin remains widely used because it addresses both insulin resistance and impaired insulin secretion. Angiotensin receptor blockers (ARBs) are commonly recommended antihypertensive agents in patients with T2DM due to their established renoprotective and cardioprotective benefits. However, accumulating experimental and clinical evidence suggests that ARBs are not metabolically inert; instead, they may influence glucose homeostasis, insulin sensitivity, and the pharmacokinetic disposition of antidiabetic drugs. These effects raise clinically relevant concerns regarding potential pharmacokinetic and pharmacodynamic interactions when ARBs are co-administered with glimepiride-metformin combinations. Preclinical investigations have demonstrated enhanced hypoglycemic responses when certain ARBs, such as losartan and telmisartan, are combined with glimepiride-metformin, possibly due to synergistic pharmacodynamic actions or alterations in drug metabolism and transport. Telmisartan, in particular, exhibits partial peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist activity, which may confer additional insulin-sensitizing effects. Clinical evidence, however, remains limited and inconsistent, with some studies suggesting modest improvements in glycemic control and others indicating an increased risk of hypoglycemia, especially in regimens containing sulfonylureas. Moreover, most available studies lack integrated pharmacokinetic-pharmacodynamic assessments and fail to reflect chronic real-world combination therapy. This review critically synthesizes current preclinical and clinical evidence on pharmacokinetic and pharmacodynamic interactions between glimepiride-metformin combinations and ARBs. It highlights existing knowledge gaps, underscores the clinical necessity for systematic and ARB specific evaluation, and proposes future research directions aimed at optimizing safety and therapeutic outcomes in patients with coexisting T2DM and hypertension.